BullsEye Insights

BullsEye: Daily London AIM RNS Round-Up

Friday 1 May 2020


Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).


Genedrive Plc (GDR.L)

Manufacturing milestones met for SARS-CoV-2 test

Genedrive ® 96 SARS-CoV-2 kit passes critical technical development milestones in Cytiva manufacturing process

Genedrive plc, the near patient molecular diagnostics company, announced it has completed the last significant manufacturing milestone in the co-development of the Genedrive® 96 SARS-CoV-2 kit with Cytiva. The PCR-based test has completed its pilot manufacturing runs and yielded high performing multiplexed assays for COVID-19 testing. The overall project plan currently remains on track and the company is targeting CE marking in approximately 3 weeks' time.

The Genedrive® 96 SARS-CoV-2 test is one of two assay programmes the Company is developing following an announcement made on 25 March 2020, with a genedrive point-of-care assay due later in the calendar year.

The Genedrive® 96 SARS-CoV-2 assay combines genedrive's PCR chemistry integrated with Cytiva's LyoStable® stabilisation technology. The combination delivers several key competitive advantages to the genedrive test compared to the liquid, kit-based assays already on market. The Genedrive® 96 SARS-CoV2-test is a final format test which only requires the addition of patient sample, with no other user preparation required. Integrated controls within each test give confidence to the user that the input sample is of good quality, and the integrity of each reaction mix is confirmed with another internal standard. The temperature-stable nature of lyophilisation technology means that the test can be transported globally without the need for refrigeration, which will support global product distribution.


For the full RNS, see: https://www.investegate.co.uk/genedrive-plc--gdr-/rns/manufacturing-milestones-met-for-sars-cov-2-test/202005010700045715L/

Avacta Group Plc (AVCT.L)

COVID-19 Antigen Diagnostic Collaboration with Adeptrix

Second partnership to exploit the recently generated Affimer binders to the SARS-COV-2 virus in a high throughput COVID-19 antigen test

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, announced that it has entered into a collaboration with Adeptrix to develop a high throughput COVID-19 antigen test using Adeptrix's proprietary bead-assisted mass spectrometry (BAMS™) platform.


Avacta and Adeptrix will collaborate to develop and manufacture an Affimer-based BAMS coronavirus antigen test  that will provide clinicians with a significant expansion of the available testing capacity for COVID-19 infection in hospitals.

Adeptrix's novel BAMS platform combines enrichment of the sample to improve sensitivity with the power of mass-spectrometry to improve specificity. Hundreds of samples per day can be analysed by a single technician using BAMS, exceeding the capacity of single PCR machine, making BAMS a very attractive high throughput technique for COVID-19 screening in the clinical setting.


The diagnostic test will allow hospitals around the world to utilise their existing installed base of mass spectrometers that are not currently used for COVID-19 testing, thus contributing significantly to the increase in global testing capacity. Avacta's recently developed Affimer reagents that bind the SARS-COV-2 spike protein will be used to provide the capture and enrichment of the virus particle from the sample which could be saliva, nasopharyngeal swabs or serum.  


Development of a BAMS test capable of diagnosing whether a person has the COVID-19 infection at any specific moment is a quick process and the companies are aiming to have a BAMS test ready for clinical validation, regulatory approval and manufacturing in June. Adeptrix and Avacta are already in discussion with large-scale manufacturing partners to rapidly deploy this new high throughput test.


Further commercial details are not being disclosed but Avacta will receive a royalty on the sales of BAMS test kits by Adeptrix.


For full RNS details, see: https://www.investegate.co.uk/avacta-group-plc--avct-/rns/covid-19-antigen-test-collaboration-with-adeptrix/202005010700055768L/

Inspiration Healthcare Group Plc (IHC.L)

NHS Orders Update

Following the announcements made on 16 March 2020 and  20 March 2020 regarding orders received from the UK National Health Service for the supply of ventilators, Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company announced that the first of the consignments of ventilators has now arrived in the UK and will shortly be shipped to a holding and distribution facility managed by the Ministry of Defence. 


In the last few days, Inspiration Healthcare has also extended its 24 hour helpline facility to give clinical staff at all UK hospitals access to qualified personnel employed by Inspiration who are able to give instructions on setting up of ventilators correctly and also to deal with any other issues which may arise during their use.  This service is now offered to all ventilators supplied to the NHS through the UK government's ventilator challenge.


For full RNS details, see: https://www.investegate.co.uk/inspiration-health--ihc-/rns/nhs-orders-update/202005010700065781L/

Download the BullsEye app for your phone or tablet

AppStore.png
playstore.png

*tap here*